Trade Mark Journal No.2026/030 24 July 2026

WO0000001927268 (5,35,42)

Office of origin: United States of America

Date of International Registration:7 May 2026
Date of designation in the UK: 7 May 2026
Image for mark 1927268

The mark consists of a stylized letter "M" formed by two overlapping curved bands.

International priority date claimed: 1 May 2026 (United States of America) (99799580)
Class 5
Pharmaceutical preparations for the treatment of cancer, infectious diseases, autoimmune disorders, and inflammatory diseases and conditions.
Class 35
New product commercialization services; business consultation and management regarding marketing activities and launching of new products; business consulting, management, and planning services in the field of product commercialization of pharmaceuticals and biotechnology; providing business information in the field of product commercialization of pharmaceuticals and biotechnology.
Class 42
Research and development in the field of pharmaceutical preparations for the treatment of cancer, infectious diseases, autoimmune disorders, and inflammatory diseases and conditions; drug discovery services; research and development in the pharmaceutical and biotechnology fields; medical and scientific research information in the field of pharmaceuticals and biotechnology.

MacroGenics, Inc.

Representative: Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C., 1101 K Street, N.W., 10th Floor, Washington DC 20005, UNITED STATES OF AMERICA